What to Do for Epilepsy with Myoclonic Absences When Adjunctive Therapies Have Failed to Control Seizures
This protocol applies to patients with drug-resistant epilepsy with myoclonic absences (EMA) who have not achieved adequate seizure control after exhausting multiple adjunctive treatment strategies.
Previous treatment line — goals not achieved
Adjunctive therapies — including addition of low-dose phenobarbital to a valproate and ethosuximide regimen, adjunctive rufinamide, vagus nerve stimulation, or ketogenic diet — did not achieve seizure freedom or at least a 50% reduction in seizure frequency.
Next-line approach
Once the above strategies have been exhausted without meeting seizure-control targets, the next step involves a palliative surgical procedure. The full protocol defines the specific options, criteria for selection, and the sequence of decision-making.
Treatment goals
- Seizure freedom
- More than 50% reduction in seizure frequency
- Complete resolution of tonic seizures
References
- Palliative corpus callosotomy may serve as a viable therapeutic alternative for children with medically refractory EMA.
- In 2022, Emma et al. demonstrated favorable outcomes in two children with drug-resistant EMA who underwent this procedure: one patient who received a full corpus callosotomy achieved seizure freedom, while another underwent anterior two-thirds corpus callosotomy experienced a reduction more than 50% in seizure frequency (from 30 to 5–10 daily episodes), with complete resolution of tonic seizures.